Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic… | ScholarDeck

Paper

Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis.

New research · Internal Medicine

Frontiers in oncology · 4w

Systematic reviewFrontiers in oncology· 2026

Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis.

Shuai Tan, Mingyue Shang, Yixian Guo … Wanling Sun

Read paper

OncologySystematic reviewTreatmentQ2IF 3.1

Adding eltrombopag to immunosuppressive therapy raises early response rates in aplastic anemia

Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis.

Shuai Tan … Wanling Sun

Frontiers in oncology · 2026

Background

Aplastic anemia (anemia) is a bone marrow failure syndrome.

Methods

The literature was retrieved from Chinese and English databases up to October 1, 2025.

n = 2,239 patients

Results

eltrombopag more than doubled the odds of early response

OR by subgroup · 95% CI

More results

There was no significant difference between the two groups at 12 months (OR = 1.14, 95% CI 0.86 - 1.51, P = 0.36, I² = 35%).

“

Conclusion · 1 of 2

The addition of eltrombopag to IST may improve early hematological responses at 3 and 6 months in patients with anemia, with no significant difference at 12 months.

Conclusion · 2 of 2

Concurrent initiation (within 7 days) was associated with earlier responses in adults.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

Cohort Study

13.5%

Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.

Review

“Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.”

Cohort Study

4.5 minutes

Each visual-field test averaged 4.5 minutes per eye.

Cohort Study

57%

eyes could see better after three ranibizumab injections

Case Report

siblings had PTEN mutation and intracranial hypertension

Cohort Study

13.16 mmHg

intraocular pressure was lower after hemodialysis

Cohort Study

HR=1.19

Every 1 mm wider portal vein was associated with a 19% higher rate of recurrent bleeding.

Cross-sectional

MYR 88,346.12

Average annual out-of-pocket expenditure for patients with cancer in Malaysia.